Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives $11.40 Consensus Price Target from Analysts

Shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM) have been assigned an average rating of “Moderate Buy” from the five research firms that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $11.40.

A number of equities research analysts recently weighed in on ATNM shares. Maxim Group decreased their price objective on Actinium Pharmaceuticals from $30.00 to $5.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. HC Wainwright decreased their price target on shares of Actinium Pharmaceuticals from $50.00 to $4.00 and set a “buy” rating for the company in a report on Tuesday, August 6th. StockNews.com lowered shares of Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday. Finally, B. Riley lowered Actinium Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $16.00 to $2.00 in a research note on Wednesday, August 7th.

Actinium Pharmaceuticals Stock Down 2.9 %

Shares of NYSE:ATNM opened at $1.66 on Tuesday. The business has a 50 day simple moving average of $1.80. The company has a market capitalization of $51.79 million, a P/E ratio of -1.11 and a beta of 0.14. Actinium Pharmaceuticals has a 52 week low of $1.33 and a 52 week high of $10.24.

Hedge Funds Weigh In On Actinium Pharmaceuticals

A number of institutional investors have recently modified their holdings of ATNM. Los Angeles Capital Management LLC purchased a new stake in Actinium Pharmaceuticals during the third quarter worth $322,000. Marshall Wace LLP boosted its stake in shares of Actinium Pharmaceuticals by 67.9% during the 2nd quarter. Marshall Wace LLP now owns 256,026 shares of the company’s stock worth $1,895,000 after acquiring an additional 103,557 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Actinium Pharmaceuticals by 6.0% during the 1st quarter. Vanguard Group Inc. now owns 1,446,326 shares of the company’s stock valued at $11,325,000 after acquiring an additional 82,113 shares during the period. Virtu Financial LLC increased its stake in shares of Actinium Pharmaceuticals by 319.2% in the 1st quarter. Virtu Financial LLC now owns 82,029 shares of the company’s stock valued at $642,000 after purchasing an additional 62,459 shares in the last quarter. Finally, Squarepoint Ops LLC acquired a new position in Actinium Pharmaceuticals in the 2nd quarter worth about $356,000. Hedge funds and other institutional investors own 27.50% of the company’s stock.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).